儿童TRK融合癌症:临床综述与筛查建议
本文综述了儿童肿瘤中NTRK1、NTRK2、NTRK3基因融合(TRK融合)的患病率及相关疾病,并鉴于选择性TRK抑制剂(如拉罗替尼在儿童和成人TRK融合癌症中显示75%缓解率)的近期进展,提供了儿童肿瘤TRK融合筛查建议:对可能携带TRK融合的肿瘤使用免疫组化或荧光原位杂交,对TRK融合患病率相对较低的肿瘤推荐下一代测序。
要点
- 婴儿纤维肉瘤、细胞性先天性中胚层肾瘤、分泌性乳腺癌和涎腺乳腺类似分泌癌几乎普遍携带TRK融合。
- TRK融合在未分化肉瘤、胶质瘤、甲状腺乳头状癌、Spitz样肿瘤、炎性肌纤维母细胞肿瘤和急性白血病等儿童癌症中以较低频率存在。
- 对可能携带TRK融合的肿瘤建议使用免疫组化或荧光原位杂交筛查,对TRK融合患病率相对较低的肿瘤推荐下一代测序。
核心结论
- 选择性TRK抑制剂(如拉罗替尼)在儿童和成人TRK融合癌症中显示75%缓解率,据此本文提供了儿童肿瘤TRK融合的筛查建议。
研究设计与样本
- 本文为J Clin Oncol发表的临床综述与筛查建议,制定机构与方法原文未报告。
主要发现
- 涉及NTRK1、NTRK2和NTRK3基因的染色体易位(TRK融合)可导致TRK激酶组成性激活和异常表达。
- 婴儿纤维肉瘤、细胞性先天性中胚层肾瘤、分泌性乳腺癌和涎腺乳腺类似分泌癌几乎普遍携带TRK融合。
- TRK融合在未分化肉瘤、胶质瘤、甲状腺乳头状癌、Spitz样肿瘤、炎性肌纤维母细胞肿瘤和急性白血病等儿童癌症中以较低频率存在。
- 拉罗替尼在儿童和成人TRK融合癌症中显示75%缓解率。
关键数值与推荐
- 对可能携带TRK融合的肿瘤患者,建议使用免疫组化或荧光原位杂交进行筛查。
- 对TRK融合患病率相对较低的肿瘤,推荐下一代测序,以识别可能从TRK抑制中获益的患者及同一肿瘤类型中其他可靶向的致癌驱动基因。
临床怎么用
- 对可能携带TRK融合的儿童肿瘤,建议使用免疫组化或荧光原位杂交筛查TRK融合。
- 对TRK融合患病率相对较低的儿童肿瘤,推荐下一代测序以识别可能从TRK抑制中获益的患者及其他可靶向致癌驱动基因。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chromosomal translocations involving the NTRK1, NTRK2, and NTRK3 genes (TRK fusions), which encode the neurotrophin tyrosine kinase receptors TRKA, TRKB, and TRKC, can result in constitutive activation and aberrant expression of TRK kinase. Certain cancers almost universally harbor TRK fusions, including infantile fibrosarcoma, cellular congenital mesoblastic nephroma, secretory breast cancer, and mammary analog secretory carcinoma of the salivary gland. TRK fusions have also been identified at lower frequencies across a broad range of other pediatric cancers, including undifferentiated sarcomas, gliomas, papillary thyroid cancers, spitzoid neoplasms, inflammatory myofibroblastic tumors, and acute leukemias. Here we review the prevalence and diseases associated with TRK fusions and methods of detection of these fusions in light of the recent development of selective TRK inhibitors, such as larotrectinib, which demonstrated a 75% response rate across children and adults with TRK fusion cancers. We provide recommendations for screening pediatric tumors for the presence of TRK fusions, including the use of immunohistochemistry or fluorescence in situ hybridization for patients with tumors likely to harbor TRK fusions. Further, we recommend next-generation sequencing for tumors that have a relatively low prevalence of TRK fusions, both to identify patients who may benefit from TRK inhibition and to identify other targetable oncogenic drivers that exist in the same tumor types.
引用
- Albert CM, Davis JL, Federman N, et al. TRK Fusion Cancers in Children: A Clinical Review and Recommendations for Screening. J Clin Oncol. 2018. PMID: 30592640. doi:10.1200/JCO.18.00573
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。